PMID-sentid Pub_year Sent_text compound_name comp_offset prot_official_name organism prot_offset 10493577-2 1999 We report low temperature, three-dimensional structures of PAP co-crystallized with adenyl-guanosine (ApG) and adenyl-cytosine-cytosine (ApCpC). apg 102-105 regenerating family member 3 alpha Homo sapiens 59-62 15553110-3 2004 In the following paper the X-ray crystal structure of rDAP as well as its complexes with cyclic AMP and adenyl-guanosine (ApG) as substrate analogs at 1.7 A resolution are reported. apg 122-125 death-associated protein Rattus norvegicus 54-58 12514955-2 2002 Partially purified azanthraquinone (AQ) extract from Mitracarpus scaber was coupled to bovine transferrin (Tf) using azidophenyl glyoxal (APG). apg 138-141 serotransferrin Bos taurus 94-105 34710737-10 2022 Mechanistically, HQP1351 downregulated expression of myeloid-cell leukemia 1 (MCL-1) by suppressing FLT3-STAT5 (signal transducer and activator of transcription 5) signaling and thus enhanced APG-2575-induced apoptosis in FLT3-ITD mutant AML cells. apg 192-195 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 53-76 34914932-8 2022 Deletion of cIAP2 from hepatocytes or degrading cIAPs by APG-1387 ameliorated liver fibrosis induced by CCl4. apg 57-60 baculoviral IAP repeat-containing 3 Mus musculus 12-17 34914932-8 2022 Deletion of cIAP2 from hepatocytes or degrading cIAPs by APG-1387 ameliorated liver fibrosis induced by CCl4. apg 57-60 chemokine (C-C motif) ligand 4 Mus musculus 104-108 34914932-11 2022 Further, MMP9 inhibition by CTT peptide, neutrophil depletion by Ly6G antibody or CCL5 deficiency blocked the anti-fibrotic effects of APG-1387 in vivo. apg 135-138 matrix metallopeptidase 9 Mus musculus 9-13 34914932-11 2022 Further, MMP9 inhibition by CTT peptide, neutrophil depletion by Ly6G antibody or CCL5 deficiency blocked the anti-fibrotic effects of APG-1387 in vivo. apg 135-138 lymphocyte antigen 6 complex, locus G Mus musculus 65-69 34710737-10 2022 Mechanistically, HQP1351 downregulated expression of myeloid-cell leukemia 1 (MCL-1) by suppressing FLT3-STAT5 (signal transducer and activator of transcription 5) signaling and thus enhanced APG-2575-induced apoptosis in FLT3-ITD mutant AML cells. apg 192-195 MCL1 apoptosis regulator, BCL2 family member Homo sapiens 78-83 34710737-11 2022 CONCLUSIONS: FLT3 inhibition by HQP1351 downregulates MCL-1 and synergizes with BCL-2 inhibitor APG-2575 to potentiate cellular apoptosis in FLT3-ITD mutant AML. apg 96-99 fms related receptor tyrosine kinase 3 Homo sapiens 13-17 34710737-11 2022 CONCLUSIONS: FLT3 inhibition by HQP1351 downregulates MCL-1 and synergizes with BCL-2 inhibitor APG-2575 to potentiate cellular apoptosis in FLT3-ITD mutant AML. apg 96-99 BCL2 apoptosis regulator Homo sapiens 80-85 34710737-11 2022 CONCLUSIONS: FLT3 inhibition by HQP1351 downregulates MCL-1 and synergizes with BCL-2 inhibitor APG-2575 to potentiate cellular apoptosis in FLT3-ITD mutant AML. apg 96-99 fms related receptor tyrosine kinase 3 Homo sapiens 141-145 33159967-9 2021 The combination therapy of APG-2449 and ibrutinib could significantly down-regulate the phosphorylation level of MEK/ERK and AKT. apg 27-30 mitogen-activated protein kinase kinase 7 Homo sapiens 113-116 33159967-9 2021 The combination therapy of APG-2449 and ibrutinib could significantly down-regulate the phosphorylation level of MEK/ERK and AKT. apg 27-30 mitogen-activated protein kinase 1 Homo sapiens 117-120 33159967-9 2021 The combination therapy of APG-2449 and ibrutinib could significantly down-regulate the phosphorylation level of MEK/ERK and AKT. apg 27-30 AKT serine/threonine kinase 1 Homo sapiens 125-128 32022261-7 2020 RESULTS: Treatment with APG-157 resulted in circulating concentrations of curcumin and analogs peaking at 3 hours with reduced IL-1beta, IL-6, and IL-8 concentrations in the salivary supernatant fluid of patients with cancer. apg 24-27 interleukin 1 alpha Homo sapiens 127-135 32022261-7 2020 RESULTS: Treatment with APG-157 resulted in circulating concentrations of curcumin and analogs peaking at 3 hours with reduced IL-1beta, IL-6, and IL-8 concentrations in the salivary supernatant fluid of patients with cancer. apg 24-27 interleukin 6 Homo sapiens 137-141 32022261-7 2020 RESULTS: Treatment with APG-157 resulted in circulating concentrations of curcumin and analogs peaking at 3 hours with reduced IL-1beta, IL-6, and IL-8 concentrations in the salivary supernatant fluid of patients with cancer. apg 24-27 C-X-C motif chemokine ligand 8 Homo sapiens 147-151